New Anticoagulant Strategies
- 1 October 1994
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 48 (4), 485-497
- https://doi.org/10.2165/00003495-199448040-00001
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.Circulation, 1994
- Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.Circulation, 1993
- Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat ModelThrombosis and Haemostasis, 1992
- Domains specifying thrombin–receptor interactionNature, 1991
- Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.Journal of Clinical Investigation, 1990
- Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombinBiochemistry, 1990
- The Structure of a Complex of Recombinant Hirudin and Human α-ThrombinScience, 1990
- Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.Proceedings of the National Academy of Sciences, 1989